Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in indian population

Asian Pacific Journal of Cancer Prevention

Volumn 8, Issue 2, 2007, Pages 275-278

  Mittal, Rama Devi ^a   Mishra, Dhruva K ^a   Mandhani, Anil ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Androgen receptor; Hormone refractory prostate cancer; North indian population

Indexed keywords

ANDROGEN RECEPTOR; DNA;

ARTICLE; BLOOD; CELL DIVISION; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; INDIA; ISOLATION AND PURIFICATION; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVOR; TRINUCLEOTIDE REPEAT;

CELL DIVISION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; GENOTYPE; HUMANS; INDIA; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SURVIVORS; TRINUCLEOTIDE REPEATS;

EID: 40449086461     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bratt O, Borg A, Kristoffersson U, et al. (1999). CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer, 81, 672-6.
2. Bubley GJ, Carducci M, Dahut W et al. (1999). Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 17, 3461-7.
3. Coetzee GA, Ross RK (1994). Re: "Prostate cancer and the androgen receptor" (Letter). J Natl Cancer Inst, 86, 872-3.
4. Cram DS, Song B, McLachlan RI, et al. (2000). CAG trinucleotide repeats in the androgen receptor gene of infertile men exhibit stable inheritance in female offspring conceived after ICSI. Mol Hum Reprod, 6, 861-6.
5. Cude KJ, Montgomery JS, Price DK et al. (2002). The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urol Int, 68, 16-23.
6. Edwards SM, Badzioch MD, Minter R et al. (1999). Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer, 84, 458-65.
7. Feldman BJ, Feldman D (2001). The development of androgenindependent prostate cancer. Nat Rev Cancer, 1, 34-45.
8. Ferlay J, Bray F, Pisani P, et al. (2001). GLOBOSCAN 2000: cancer incidence, mortality and prevalence worldwide. Lyon, International Agency for Research on Cancer.
9. Giovannucci E, Stampfer MJ, Krithivas K et al. (1997). The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci, 94, 3320-3.
10. Gittes RF (1991). Carcinoma of the prostate. N Engl J Med, 324, 236-45.
11. Haapala K, Hyytinen ER, Roiha M, et al. (2001). Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest, 81,1647-51.
12. Hakimi JM, Schoenberg MP, Rondinelli RH, et al. (1997). Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res, 3, 1599-608.
13. Hardy DO, Scher HI, Bogenreider T et al. (1996). Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab, 81, 4400-5.
14. Laufer M, Denmeade SR, Sinibaldi VJ, et al. (2000). Complete androgen blockade for prostate cancer: what went wrong? J Urol, 164, 3-9.
15. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
16. Mononen N, Ikonen T, Autio V et al. (2002). Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet, 111, 166-171.
17. Nazareth LV, Weigel NL (1996). Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem, 271, 19900-7
18. Palmberg C, Koivisto P, Kakkola L, et al. (2000). Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol, 164, 1992-5.
19. Sadar MD, Gleave ME (2000). Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res, 60, 5825-31.
20. Sinha R, Anderson DE, McDonald SS (2003), Greenwald P. Cancer risk and diet in India. J Postgrad Med, 49, 222-8.
21. Sun Z, Pan J, Balk SP (1997). Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes, NAR, 25, 3318-25.
22. Zegarra-Moro OL, Schmidt LJ, Huang H, et al. (2002). Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res, 62, 1008-13